SpyGlass Pharma, Inc. Common Stock (SGP) Stock
Key stats
- Market cap
- $1.17B
- Price / Earnings ratio
- -28.7x
- EPS (TTM)
- -$17.98
- Volume
- Loading
- 52-week high
- $39.92
- 52-week low
- $17.06
Source: third-party data provider, as of November 13, 2026
Compare with SGP
Technical indicators
- RSI 14
- 62.91
- MACD 12/26/9
- 2.50
- EMA 9 of MACD
- 2.12
- MACD histogram
- 0.38
- SMA 50
- $28.60
- Price above SMA 50
- EMA 50
- $29.14
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About SpyGlass Pharma, Inc. Common Stock
The company is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company seeks to improve patient outcomes by developing durable drug delivery solutions that support long-term disease control and vision preservation, providing confidence for both patients and surgeons. Its lead product candidate, the Bimatoprost Drug Pad–Intraocular Lens System (BIM-IOL System), consists of novel, proprietary drug pads attached to an intraocular lens (IOL) and is designed for implantation during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Patrick H. Mooney | CEO & Director | 1974 |
| Dr. Malik Y. Kahook M.D. | Co-Founder, President, Chief Medical Officer & Executive Chairman | 1975 |
| Dr. Jean-Frederic Viret Ph.D. | Chief Financial Officer | 1966 |
| Mr. James Robert Dennewill Jr. | Chief Operating Officer | 1981 |
| Dr. Chetan Pujara Ph.D. | Chief Research & Development Officer | 1970 |
| Mr. Glenn Sussman | Co-founder & Chief Technology Advisor | 1964 |
| Ms. Shannon Trevino J.D. | General Counsel | — |
| Mr. Mike Pinder | Vice President of Marketing | — |
| Ms. Rachel Gilette | Vice President of Human Resources | — |
| Mr. Paul Yoo O.D. | Senior Vice President of Clinical Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.91
- MACD 12/26/9
- 2.50
- EMA 9 of MACD
- 2.12
- MACD histogram
- 0.38
- SMA 50
- $28.60
- Price above SMA 50
- EMA 50
- $29.14
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $37.00
- Average
- $38.00
- High
- $39.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +6.1 | -3.1 | -6.1 | -19.7 | +21.5 | +15.7 | +15.1 | -3.2 | +21.7 | +1.6 |
